Gary Zammit

Best Publications

• Short Sleep Duration as a Risk Factor for Hypertension Analyses of the First National Health and Nutrition Examination Survey

  James E. Gangwisch;Steven B. Heymsfield;Bernadette Boden-Albala;Ruud M. Buijs

  1667
  Citations

• Sleep Duration as a Risk Factor for Diabetes Incidence in a Large US Sample

  James E. Gangwisch;Steven B. Heymsfield;Bernadette Boden-Albala;Ruud M. Buijs

  739
  Citations

• Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes

  Gary D. Foster;Mark H. Sanders;Richard Millman;Gary Zammit

  738
  Citations

• Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.

  A Blackman;G D Foster;G Zammit;R Rosenberg

  543
  Citations

• An efficacy, safety, and dose–response study of Ramelteon in patients with chronic primary insomnia

  Milton Erman;David Seiden;Gary Zammit;Stephen Sainati

  387
  Citations

• Earlier Parental Set Bedtimes as a Protective Factor Against Depression and Suicidal Ideation

  James E. Gangwisch;Lindsay A. Babiss;Dolores Malaspina;J. Blake Turner

  358
  Citations

• Long-Term Effect of Weight Loss on Obstructive Sleep Apnea Severity in Obese Patients with Type 2 Diabetes

  Samuel T Kuna;Samuel T Kuna;David M Reboussin;Kelley E Borradaile;Mark H Sanders

  272
  Citations

• Short sleep duration as a risk factor for hypercholesterolemia: analyses of the National Longitudinal Study of Adolescent Health.

  James E. Gangwisch;Dolores Malaspina;Lindsay A. Babiss;Mark G. Opler

  268
  Citations

• Sleep duration associated with mortality in elderly, but not middle-aged, adults in a large US sample.

  James E. Gangwisch;Steven B. Heymsfield;Bernadette Boden-Albala;Ruud M. Buijs;Ruud M. Buijs

  266
  Citations

• Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials

  Unknown

  264
  Citations

• Long-Term Efficacy and Safety of Zolpidem Extended-Release 12.5 mg, Administered 3 to 7 Nights Per Week for 24 Weeks, in Patients With Chronic Primary Insomnia: A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study

  Andrew D. Krystal;Milton Erman;Gary K. Zammit;C. Soubrane

  258
  Citations

• Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia.

  Gary Zammit;Milton Erman;Sherry Wang-Weigand;Stephen Sainati

  251
  Citations

• A new questionnaire to detect sleep disorders.

  Thomas Roth;Gary Zammit;Clete Kushida;Karl Doghramji

  250
  Citations

• Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.

  Sheldon Preskorn;Matthew Macaluso;Do Vishaal Mehra;Gary Zammit

  230
  Citations

• Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial

  Russell Rosenberg;Patricia Murphy;Gary Zammit;David Mayleben

  228
  Citations

• Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.

  Gary K. Zammit;Louis J. McNabb;Judy Caron;David A. Amato

  184
  Citations

• Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.

  Paula K Schweitzer;Russell Rosenberg;Gary K Zammit;Mark Gotfried

  173
  Citations

• Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.

  Patricia Murphy;Margaret Moline;David Mayleben;Russell Rosenberg

  169
  Citations

• Hypoglossal nerve stimulation improves obstructive sleep apnea: 12-month outcomes.

  Eric J. Kezirian;George S. Goding;Atul Malhotra;Fergal J. O'Donoghue

  166
  Citations

• Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.

  Mikko Kärppä;Jane Yardley;Kate Pinner;Gleb Filippov

  137
  Citations